Navigation Links
Syngenta Opens Unique $72 Million Advanced Crop Lab
Date:5/17/2013

ed the new plant research facility.

“Syngenta invests more than $1.25 billion annually to directly focus on solving challenges for farmers. As we consider global food security, the research conducted in our new crop lab will be essential to meet that demand,” said Vern Hawkins, Syngenta North America region director.

Design elements of the new facility include insulated glass walls that provide a virtually shadowless indoor environment, a liquid “fertigation” system to feed and water the plants and an automated roof-washing system. The building is Green Globes Certified, which recognizes the company’s sustainable construction processes. In constructing the new facility, Syngenta reclaimed a former industrial site and recycled more than 85 percent of those materials.

The 136,000-square-foot facility is located within the 50-acre Syngenta RTP Innovation Center. Construction began in 2011 and was performed by nearly 300 local contractors, requiring roughly 500,000 man-hours to complete. Syngenta added 15 highly-skilled jobs to its existing RTP workforce.

For an RTP Innovation Center media kit, including speaker biographies, photos for media use and more, please visit: http://www.syngentabiotech.com/news_releases/news.aspx?id=147583.

Twitter @SyngentaBiotech
Facebook Facebook.com/FarmAssist

About Syngenta

Syngenta is one of the world's leading companies with more than 27,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers, we help to increase crop productivity, protect the environment and improve health and quality of li
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Syngenta and Devgen enter insect control research partnership
2. Syngenta to acquire Pasteuria Bioscience
3. Pasteuria Bioscience to be Acquired by Syngenta
4. Syngenta Secures EU Approval For Next Generation Fungicide
5. Syngenta divests US flowers distribution and brokerage
6. Ceres and Syngenta to Collaborate on Sweet Sorghum Market Development
7. Syngenta Licenses Plant Sensory Systems' Technology
8. Bayer CropScience and Syngenta Submit Herbicide-tolerance Soybean Trait for Approval in Various Countries
9. Syngenta and Bayer CropScience Propose a Comprehensive Action Plan to Help Unlock EU Stalemate on Bee Health
10. Syngenta Holds Annual General Meeting
11. First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Boston, MA (PRWEB) July 31, 2014 ... ) finds itself flush with innovative adult stem cell ... patents and has three additional patent applications ... Office. , The patented inventions address two of the ... and regenerative medicine. Adult stem cells are difficult ...
(Date:7/30/2014)... , July 30, 2014  Decision Resources ... and medical directors in the United ... of biosimilar market penetration will be the level ... (MCOs) and the expected lower cost to patients. ... biosimilars that meet their pricing expectations in order ...
(Date:7/30/2014)... 2014 Selexis SA , a ... discovery and mammalian cell line development, announced today new ... will be presented at the 10th Annual Cell ... 8 – 10, 2014 at the Double Tree by ... following abstract will be presented during an oral presentation: ...
(Date:7/30/2014)... 30, 2014 BCC Research ( http://www.bccresearch.com ... for Enzymes in Industrial Applications , the global market ... $7.1 billion by 2018, registering a five-year compound annual ... to be recorded in the detergent enzyme segment with ... Enzyme technology has influenced almost every sector of industrial ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3
... N.J., Sept. 30 Informex ( http://www.informex.com ... of high-value chemistry for a broad range of applications, ... will occur on November 9, 2010 in Milwaukee, Wisconsin. ... Informex initiative to act as a knowledge conduit for ...
... Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in... -- COPENHAGEN, September 30, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... Offer for Movetis NV and Commencement of... -- DUBLIN, September 30, 2010 ... ... --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
Cached Biology Technology:Inaugural Pharma Exchange Conference Produced by Informex to Draw Together Milwaukee, Wisconsin Chemical Industry 2Inaugural Pharma Exchange Conference Produced by Informex to Draw Together Milwaukee, Wisconsin Chemical Industry 3Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 2Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 3Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 4Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 5Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 6Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 7Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 8Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 9Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 10Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 2Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 3Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 4Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 5Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 6Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 7Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 8
(Date:7/30/2014)... Scientists are searching through a massive collection of ... 50 years ago, and the effort is yielding fresh ... inhabited. , When the collection is fully curated, a ... the largest unbiased Dominican amber collection in the world, ... discovery thus far is that of a pygmy locust, ...
(Date:7/30/2014)... subject of major interest in neuroscience. A large ... distinct stages of Wallerian degeneration: transcription factor activation, ... gene expression responses in the distal segment of ... known, differences in gene expression between the proximal ... and co-workers from Nantong University, China used microarrays ...
(Date:7/30/2014)... analysis of the roughly 3,000 pieces is still in ... the results will be of major significance. "Amazingly often, ... species in Fushun amber that we found in Baltic ... , The Baltic amber comes from the Baltic Sea ... rich in finds are, e.g., the coastal regions of ...
Breaking Biology News(10 mins):Decades-old amber collection offers new views of a lost world 2Chinese mosquitos on the Baltic Sea 2
... invading virus hijacks a cell,s workings by imitating a ... cell signals, the virus destroys a defensive protein designed ... cell cultures, may represent a broader targeting strategy used ... for developing more effective treatments for infectious diseases. ...
... Escherichia coli a bacteria considered the ... is a friend. Cornell University biomolecular engineers have learned ... proteins for making pharmaceuticals cheaper and faster. ( Nature ... Cornell associate professor of chemical and biomolecular engineering, and ...
... (a treatment that involves temporarily inserting and blowing up ... widen it) on veins in the neck and chest ... the venous abnormalities found in those with multiple sclerosis ... the Society of Interventional Radiology,s 37th Annual Scientific Meeting ...
Cached Biology News:To drive infections, a hijacking virus mimics a cell's signaling system 2From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals 2Interventional radiology: Mitigating symptoms, improving quality of life of MS patients 2Interventional radiology: Mitigating symptoms, improving quality of life of MS patients 3
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
Request Info...
SAIVI Alexa Fluor 680 injectable contrast agent *bovine serum albumin*...
RABBIT ANTI QUINOLINIC ACID...
Biology Products: